“Ultimovacs announced yesterday that it will be participating in a phase II study in collaboration with AstraZeneca, along with the Nordic Society of Gynaecological Oncology (NSGO) and the European Network of Gynaecological Oncological Trial Groups (ENGOT). The aim of the randomized clinical trial is to evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer.”
Read the full article here